Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

Recruiting

• Conditions: Chronic Pain
• Interventions: Genetic: BDNF analysis (Elisa KIT)

• Registration Number: NCT05736575
• Lead Sponsor: Universidad Autonoma de Madrid

Brief Summary

A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.

Detailed Description

Brain-derived neurotrophic factor (BDNF) is considered a biomarker of brain plasticity. Since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.

Study Timeline

• Study First Submitted: 2023-02-09
• Study First Submitted QC: 2023-02-18
• Study First Posted: 2023-02-21
• Study Start: 2023-05-15
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-29
• Last Update Posted: 2023-11-30
• Primary Completion: 2024-02-28
• Study Completion: 2024-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months
• patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle
• not having received physiotherapy treatment for this same process in the last 3 months.
• ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.

Exclusion Criteria

• Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic Pain Patient	BDNF analysis (Elisa KIT)	A blood draw is to be performed to analyze peripheral BDNF.
Asymptomatic subject	BDNF analysis (Elisa KIT)	A blood draw is to be performed to analyze peripheral BDNF.

Primary Outcome Measures

Name	Time	Method
BDNF Levels	3 hours	Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer \[1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer\], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker.
Pain Intensity	3 hours	Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable"

Trial Locations

Locations (1)

Irf Cseuls; 🇪🇸 Madrid, Spain